Skip to main content

Advertisement

Table 1 Baseline characteristics of the patients included in the analyses

From: Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

  Tocilizumab plus methotrexate Tocilizumab Methotrexate
sDFR (n = 14) Controls (n = 5) sDFR (n = 13) Controls (n = 11) sDFR (n = 10) Controls (n = 7)
Female gender, n (%) 6 (43) 4 (80) 9 (69) 8 (73) 8 (80) 6 (86)
Age (years) 53 (16) 64 (10) 58 (14) 51 (13) 50 (14) 46 (17)
BMI (kg/m2) 25 (4) 27 (4) 25 (2) 25 (5) 29 (4) 26 (3)
Caucasian, n (%) 13 (93) 4 (80) 13 (100) 10 (91) 10 (100) 7 (100)
Current smokers, n (%) 3 (21) 1 (20) 2 (15) 3 (27) 1 (10) 1 (14)
Symptom duration (days), median (IQR) 22 (21–40) 19 (14–55) 24 (18–39) 21 (16–25) 30 (13–40) 31 (20–45)
RF positive, n (%) 5 (34) 3 (60) 8 (62) 6 (55) 9 (90) 5 (71)
Anti-CCP positive, n (%) 5 (34) 3 (60) 8 (62) 7 (64) 7 (70) 6 (86)
CRP (mg/L), median (IQR) 5 (2–13) 5 (4–9) 15 (4–27) 14 (4–30) 11 (5–18) 5 (4–12)
ESR (mm/h), median (IQR) 18 (12–39) 25 (23–29) 26 (14–28) 20 (9–39) 25 (13–47) 16 (13–25)
DAS28 (range 0–9.4, 9.4 = maximum) 4.7 (1.2) 5.1 (0.9) 5.0 (1.1) 5.3 (1.3) 4.6 (1.2) 4.8 (0.9)
HAQ (range 0–3, 3 = worst function) 0.8 (0.5) 1.5 (0.9) 1.0 (0.6) 1.4 (0.7) 0.9 (0.6) 1.0 (0.5)
Sharp/van der Heijde score, median (IQR) 0 (0–0) 0 (0–0) 0 (0–3) 0 (0–2) 0 (0–1) 0 (0–0)
  1. Continuous data presented as mean (SD) unless otherwise indicated
  2. SD standard deviation, IQR interquartile range, sDFR sustained drug-free remission, BMI body mass index, RF rheumatoid factor, CCP cyclic citrullinated peptide, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score assessing 28 joints, HAQ health assessment questionnaire